Articles tagged "Monoclonal antibodies"

2020 American Transplant Congress
Three-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection – Early Impact of Interleukin-6 Blockade on Donor-Specific Antibody Levels, Rejection Morphology and Gene Expression
G. A. Böhmig¹, M. Dürr², B. Jilma³, F. Eskandary¹, E. Chong⁴, S. Schranz³, K. Doberer¹, M. Wahrmann¹, A. Borski¹, H. Regele⁵, J. Kläger⁵, R. Reindl-Schwaighofer¹, J. Reeve⁶, K. Budde², P. F. Halloran⁶
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Nephrology Department, Charité Berlin, Berlin, Germany, ³Dept. of Clin. Pharmacology, Medical University of Vienna, Vienna, Austria, ⁴Vitaeris Inc., Vancouver, BC, Canada, ⁵Dept. of Clin. Pathology, Medical University of Vienna, Vienna, Austria, ⁶Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Targeting Interleukin-6 (IL-6) is a promising strategy to counteract antibody-mediated rejection (ABMR). This phase 2 trial (NCT03444103) was designed to evaluate the safety and…
2020 American Transplant Congress
New Strategy to Maximize Nanomedicine Delivery During Ex Vivo Organ Perfusion
C. Albert¹, L. Bracaglia¹, A. Koide², C. M. Edwards³, T. Lysyy³, J. S. Pober⁴, M. Saltzman¹, S. Koide², G. Tietjen³
¹Biomedical Engineering, Yale University, New Haven, CT, ²Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, ³Surgery, Yale University, New Haven, CT, ⁴Immunobiology, Yale University, New Haven, CT
*Purpose: Organ transplant is a highly successful therapy for patients facing end stage organ failure. However, there is a severe lack of transplantable organs which…
2020 American Transplant Congress
Early Impact of Interleukin-6 Blockade on the Distribution of Peripheral Blood Immune Cell Subpopulations – 3-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection
K. A. Doberer¹, G. A. Boehmig¹, M. Streitz², S. Schlickeiser², F. Bauernfeind¹, A. Spittler³, B. Jilma⁴, F. Eskandary¹, E. Chong⁵, S. Schranz⁴, K. Budde⁶, M. Dürr⁶
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Charité Universitätsmedizin Berlin, Institute of Medical Immunology, Berlin, Germany, ³Center of Translational Research, Medical University of Vienna, Vienna, Austria, ⁴Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, ⁵Vitaeris Inc., Vancouver, BC, Canada, ⁶Division of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Interleukin-6 (IL-6) is considered to play a critical role within the multifacted pathophysiological process of antibody-mediated rejection (ABMR), including modulation of regulatory T cells…
2020 American Transplant Congress
CD38 Antibody Daratumumab for the Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection
K. Doberer¹, J. Kläger², G. A. Gualdoni¹, K. Mayer¹, F. Eskandary¹, H. Agis³, T. Reiter¹, R. Reindl-Schwaighofer¹, M. Wahrmann¹, G. Cohen¹, H. Haslacher⁴, G. Bond¹, I. Simonitsch-Klupp⁵, I. Farkash⁶, P. Halloran⁷, G. A. Böhmig¹
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Dept. of Clin. Pathology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine I, Medical University of Vienna, Vienna, Austria, ⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁵Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁶Dept. of Pathology, University of Michigan, Ann Arbor, MI, ⁷Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Late antibody-mediated rejection (ABMR) is a major cause of transplant failure. Potential therapeutic targets are plasma cells (PC) and natural killer (NK) cells expressing…
2020 American Transplant Congress
Long Term Outcomes of Kidney Transplantation in Patients with AL-Amyloidosis – The Mayo Clinic Experience
A. Bentall¹, C. Heybali², J. Wen³, A. Hatem¹, C. A. Schinstock¹, E. Lorenz¹, M. El Ters¹, M. Mai⁴, H. Khamash⁵, D. Murray⁶, M. D. Stegall⁷, F. G. Cosio¹, M. P. Alexander⁶, N. Leung¹
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ²School of Medicine, Dokuz Eylul University, Izmir, Turkey, ³National Clinical Research Center of Kidney Disease, Jinling Hospital, Nanjing, China, ⁴Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, ⁵Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ, ⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁷Department of Transplant Surgery, Mayo Clinic, Rochester, MN
*Purpose: New clone-directed therapies and better definition of hematological response criteria allows assessment of post-kidney transplantation outcomes in patients with light-chain (AL) amyloidosis*Methods: Patients with…
2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
R. M. Hofmann¹, J. Combs², K. J. Schmidt³, T. Dyckman⁴
¹Nephrology, Renal Associates of West Michigan, Grand Rapids, MI, ²Pharmacy/Transplant, Mercy Health St. Mary's, Grand Rapids, MI, ³Pharmacy, Ferris State University College of Pharmacy, Big Rapids, MI, ⁴Pharmacy, Mercy Health St. Mary's, Grand Rapids, MI
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…
2020 American Transplant Congress
Risk of Histological Relapse in Patients with Monoclonal Gammopathy of Renal Significance after Kidney Transplantation
A. Bentall¹, C. Heybeli², F. G. Cosio¹, M. El Ters¹, N. Leung¹, M. P. Alexander³
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ²Department of Internal Medicine, Dokuz Eylul University, Izmir, Turkey, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
*Purpose: There is increased recognition of Monoclonal Gammopathy of Renal Significance (MGRS) but data on kidney transplant (ktx)outcomes are lacking. We assessed KTX outcomes of…
2020 American Transplant Congress
Pneumocystis Pneumonia Occurrence and Prophylaxis Duration in Kidney Transplant Recipients According to Perioperative Treatment with Rituximab
Y. Ko, Y. Kim, D. Han, H. Kwon
Department of Surgery, Division of Kidney and Pancreas Transplant, AMC, Seoul, Korea, Republic of
*Purpose: Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving…
2019 American Transplant Congress
The Effects of Anti-BAFF Monoclonal Antibody in the HLA-A2 Sensitized Mouse Model
J. Min¹, H. Lee², B. Kim³, K. Park⁴, K. Doh³, T. Kim⁵, H. Yoon⁶, C. Yang⁷, E. Oh², B. Chung⁷
¹Division of Nephrology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Korea, Republic of, ²Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ³Convergent Research Consortium for Immunologic Disease, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁴Department of Molecular & Cell Biology, Graduate School, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁵Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁶Division of Nephrology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea, Republic of, ⁷Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: B-cell activating factor (BAFF) is a cytokine that plays a role in the survival, proliferation and differentiation of B-cells. The aim of this study…
2019 American Transplant Congress
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Solid Organ Transplant Recipients at an Academic Medical Center
J. S. Kerr, N. Law, S. Aslam
Center for Transplantation, University of California, San Diego Health System, La Jolla, CA
*Purpose: In the United States, the incidence of Clostridium difficile infection (CDI) has increased remarkably and remains a significant burden in the solid organ transplant…